VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model.

Abstract excerpt

VEGF165b has been shown to be an effective anti-cancer agent; however, its short half-life limits further application in the clinical field. The development of a mutant VEGF165b with a prolonged half-life is urgently needed for its future application. A mutant VEGF165b was generated by inactivation of its plasmin cleavage site. The mutant and native VEGF165b proteins without purification tags were expressed via...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Vascular Endothelial Growth Factor A
• Share to Half-Life